Respected mam, thank you for sharing this mcq. Clinical diagnosis : ACUTE NEPHRITIC SYNDROME with ACUTE KIDNEY INJURY (AKI): 1. Hypertension 2. Hematuria 3. Raised serum creatinine Biopsy : Crescentric changes. Now with h/o acute renal failure with crescents the patient is suffering from RAPIDLY PROGRESSIVE GLOMEULONEPHRITIS (RPGN). Hence thr most likely diagnosis in this case is RPGN. Ans : D ( RPGN) SLE (option E) is a systemic disease and a known cause of RPGN. This patient needs to be further evaluated ( ANA, Anti ds DNA, Anti Sm antibodies)and clinical criteria to rule out SLE. Immunofluorescence in SLE may show a characteristic full house pattern ( positive for IgG, IgM, IgA, C3 and fibrinogen). Also the most common cause of RPGN is ANCA mediated i.e Wegeners, microscopic polyangitis. Hence serum ANCA studies needs to be done. With the provided details it's a case of RPGN. The patient needs to be evaluated further for the etiology. Thank you mam. Regards...
RPGN. Here we need to be aggressive in diagnosis and management. causes like Anti GBM antibodies need to be evaluated and promptly started on plasmapheresis or immunosuppression along with hemodialysis...
A- Diabetic nephropathy.
Cases that would interest you
- Login to View the image
33 yr old female pt comes with h/o multiple joint pains & rash over the face, o/e no obvious joint deformities. systemic exam - normal. how to approach this case ?Dr. Amith Gupta2 Likes31 Answers
- Login to View the image
WHAT IS MPGN Membranoproliferative glomerulonephritis (MPGN) is a disease that affects the glomeruli, or filters, of the kidneys. Most instances of MPGN are caused by other diseases or disorders, including autoimmune diseases (such as systemic lupus erythematosis), chronic infections (like hepatitis B or more commonly hepatitis C), monoclonal immunoglobulin deposition diseases, and hereditary diseases. However, a few cases are idiopathic, or of unknown cause. The idiopathic type of MPGN is seen more commonly in persons aged 8-40 MICROSCOPIC TYPES There are three histologic (microscopic) types of MPGN, each of which has a different appearance under the microscope. Type I– Discrete immune complexes are found in the mesangium and subendothelial space. Immune complexes are combinations of antigens and antibodies which bind to each other and then become lodged in the kidney. This activates the immune system, which causes inflammation and damage to the kidney itself. Type II – This is also called dense deposit disease. When viewed under the microscope, continuous, dense ribbon-like deposits are found along the basement membranes of the glomeruli, tubules, and Bowman’s capsule. Type III – This is also an immune complex disease, similar to Type I. However, the immune complexes are found in the subepithelial space, and there is disruption of the glomerular basement membrane with large open areas. What are the symptoms? The symptoms of MPGN are very similar to those of a focal glomerulonephritis. Specifically, patients have hematuria (blood in the urine), either macroscopic, which can be seen by the naked eye, or microscopic. Many of the red blood cells are dysmorphic (malformed or misshapen). In addition, mild or severe proteinuria can be found (including the nephrotic syndrome). What is the treatment? When MPGN is associated with another condition or disease, it is usually resolved by successfully treating the associated condition or disease. However, the optimal treatment of idiopathic MPGN is not entirely known. The type of treatment will depend on the type of proteinuria that the patient has. If a patient has proteinuria that is “non-nephrotic”, then specific immunosuppressive therapy may not be necessary, as the long-term outcome is not life-threatening. However, patients with nephrotic-range proteinuria will typically be treated with steroids (Prednisone).Sushmita Haodijam2 Likes1 Answer
- Login to View the image
RENAL FEATURES OF SLE/SLE NEPHRITIS. Lupus nephritis is inflammation of kidneys caused by SLE.Systemic lupus erythematosus is an auto immune disease in which the body's immune system attacks the body's own cells and organs.SLE nephritis gets worse over time and leads to renal failure. Lupus is more common in woman than in men. 9 out of 10 lupus patients are women.It most often strikes during child bearing years.Lupus is also more common in poeple of asian or african background. SYMPTOMS OF LUPUS NEPHRITIS. 1.Sudden ,unexplained swelling ,especially in the extremities-feet,ankles,legs,fingers,arms or eyes. 2.Hematuria. 3.Elevated blood pressure. 4.Foamy appearance in urinedue to proteinuria 5.Increased urination ,especially at night. HYPERTENSION,HEMATURIA,PROTEINURIA, EDEMA &WEIGHT GAIN CLASSIFICATION OF LUPUS NEPHRITIS. Lupus nephritis is staged according to the classification revised by the international society of nephrology (ISN) amd Renal pathology society (RPS).in 2003.The classification is based on light microscopy, immunoflorescence and electron microscopy findings from renal biopsy specimens. ISN/RPS CLASSIFICATION CLASS I : MINIMAL MESANGIAL LUPUS NEPHRITIS. Histological features. *Normal glomeruli on light microscopy. *Mesangial immune deposits on immunoflorescence. CLASS II : MESANGIAL LUPUS NEPHRITIS. Histological features. Mesangial hypercellularity with mesangial immune deposits on immunoflorescence. CLASS III : FOCAL PROLIFERATIVE. LUPUS NEPHRITIS. Histological features. Focal proliferative glomerulonephritis involving <<50% of glomeruli.,typically with focal sub- endothelial immune deposits and leucocyte infiltration. CLASS IV : DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS. Histological features. Diffuse proliferative glomerulonephritis involving >>>50 % of glomeruli ,typically diffuse sub -endothelial immune deposits. CLASS V : MEMBRANOUS LUPUS NEPHRITIS Histological features. Thickening of capillary walls. Global/segmental sub-epithelial immune deposits. CLASS VI : ADVANCED SCLEROSIS LUPUS NEPHRITIS. Histological features. Irreversible advanced disease. >>>90 % glomerulosclerosis. PATHOPHYSIOLOGY OF SLE Multiple influences are thought to underlie the pathogenesis of SLE like 1.Genetic factors. 2.Epigenetic modifications. 3.Environmental triggers. 4.Hormonal influences. 5.Aberrant immune mechanismslike Adaptive immune dysfunction. Innate immune dysfunction. LABORATORY DIAGNOSIS. Laboratory tests to evaluate renal function in SLE are 1.Blood urea nitrogen (BUN ) testing. 2.Serum creatinine assessment. 3.Urine analysis - to check for protein,RBC casts, and cellular casts. 4.Spot urine test for creatinine and protein concentration. Laboratory tests to evaluate SLE disease activity are 1.Antibodies to double stranded DNA (ds DNA) 2.Complement(C3,C4,and CH50.). 3.ESR. 4.C-reactive protein.(CRP). RENAL BIOPSY is considered in any patient with SLE who has clinical or laboratory evidence of active nephritis ,especially upon the first episode of nephritis . MANAGEMENT. THE PRINCIPAL GOAL OF THERAPY IN LUPUS NEPHRITIS IS TO NORMALISE RENAL FUNCTION OR,ATLEAST ,TO PREVENT THE PROGRESSIVE LOSS OF RENAL FUNCTION. Key points of American college of Rheumatology guidelines for managing lupus nephritis are as follows 1.Patients with clinical evidence of active, previously untreated lupus nephritis should have a RENAL BIOPSY to classify the disease according to ISN/RPS criteria. 2.All patients with lupus nephritis should receive background therapy with HYDROXYCHLOROQUINE ,unless contra indicated. 3.GLUCOCORTICOIDS along with CYCLOPHOSPHAMIDE intra venously (OR ) MYCOPHENOLATE MOFETIL orally should be administered to Patients with CLASS III/IV disese. Patients with class I/II nephritis do not require immunosuppressant therapy. 4.ACE INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS should be administered if proteinuria exceeds 0.5 gm/day. 5.B.P should be maintained below 130/80 mm Hg. Patients with CLASS V. lupus nephritis are generally treated with prednisone for 1-3months ,followed by tapering for 1-2 years , if a response occurs. INVESTIGATIONAL THERAPIES FOR SLE NEPHRITIS. 1.Rituximab 2.Other anti-CD20 monoclonal antibodies like Ocrelizumab. Ofatumumab. Epratuzumab. TRU-015. 3.Belimumab. 4.Atacicept. 5.Abetimus. 6.Anti-cytokine therapies. Patients with end stage renal disease require DIALYSIS and are good candidates for RENAL TRANSPLANTATION.Hemodialysis is preferred to peritoneal dialysis. MY DOUBT: WONT THAT TRANSPLANTED KIDNEY BE AFFECTED BY SLE?????Dr. Suvarchala Pratap10 Likes6 Answers
- Login to View the image
A 11 year old boy has presented with recurrent episodes of haemoptysis and also haematuria. no association with any infection. on examination a large ulcer was present on the pharynx and septum of nose destroyed diagnosis and further management?Dr. Raghav Yelamanchi6 Likes8 Answers
- Login to View the image
Lupus is a chronic autoimmune disease in which the body’s immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Under normal function, the immune system makes proteins called antibodies in order to protect and fight against antigens such as viruses and bacteria. Lupus makes the immune system unable to differentiate between antigens (a substance capable of inducing a specific immune response) and healthy tissue. This leads the immune system to direct antibodies against the healthy tissue – not just antigens – causing swelling, pain, and tissue damage. History The history of lupus can be divided into three periods: classical, neoclassical, and modern. This article concentrates on developments in the present century which have greatly expanded our knowledge about the pathophysiology, clinical-laboratory features, and treatment of this disorder. Lupus in the classical period (1230-1856) The history of lupus during the classical period was reviewed by Smith and Cyr in 1988. Of note are the derivation of the term lupus and the clinical descriptions of the cutaneous lesions of lupus vulgaris, lupus profundus, discoid lupus, and the photosensitive nature of the malar or butterfly rash. The word ‘lupus’ (Latin for ‘wolf’) is attributed to the thirteenth century physician Rogerius who used it to describe erosive facial lesions that were reminiscent of a wolf’s bite. Classical descriptions of the various dermatologic features of lupus were made by Thomas Bateman, a student of the British dermatologist Robert William, in the early nineteenth century; Cazenave, a student of the French dermatologist Laurent Biett, in the mid-nineteenth century; and Moriz Kaposi (born Moriz Kohn), student and son-in-law of the Austrian dermatologist Ferdinand von Hebra, in the late nineteenth century. The lesions now referred to as discoid lupus were described in 1833 by Cazenave under the term “erythema centrifugum,” while the butterfly distribution of the facial rash was noted by von Hebra in 1846. The first published illustrations of lupus erythematosus were included in von Hebra’s text, Atlas of Skin Diseases, published in 1856. Lupus in the neoclassical period (1872- 1948) The Neoclassical era of the history of lupus began in 1872 when Kaposi first described the systemic nature of the disorder: “…experience has shown that lupus erythematosus … may be attended by altogether more severe pathological changes, and even dangerous constitutional symptoms may be intimately associated with the process in question, and that death may result from conditions which must be considered to arise from the local malady.” Kaposi proposed that there were two types of lupus erythematosus; the discoid form and a disseminated (systemic) form. Furthermore, he enumerated various signs and symptoms which characterized the systemic form, including: subcutaneous nodules arthritis with synovial hypertrophy of both small and large joints lymphadenopathy fever weight loss anemia central nervous system involvement The existence of a systemic form of lupus was firmly established in 1904 by the work of Osler in Baltimore and Jadassohn in Vienna. Over the next thirty years, pathologic studies documented the existence of nonbacterial verrucous endocarditis (Libman-Sacks disease) and wire-loop lesions in individuals with glomerulonephritis; such observations at the autopsy table led to the construct of collagen disease proposed by Kemperer and colleagues in 1941. This terminology, ‘collagen vascular disease,’ persists in usage more than seventy years after its introduction. Lupus in the modern era (1948-present) The sentinel event which heralded the modern era was the discovery of the LE cell by Hargraves and colleagues in 1948. The investigators observed these cells in the bone marrow of individuals with acute disseminated lupus erythematosus and postulated that the cell “…is the result of…phagocytosis of free nuclear material with a resulting round vacuole containing this partially digested and lysed nuclear material…”. This discovery ushered in the present era of the application of immunology to the study of lupus erythematosus; it also allowed the diagnosis of individuals with much milder forms of the disease. This possibility, coupled with the discovery of cortisone as a treatment, changed the natural history of lupus as it was known prior to that time. Two other immunologic markers were recognized in the 1950s as being associated with lupus: the biologic false-positive test for syphilis and the immunofluorescent test for antinuclear antibodies. Moore, working in Baltimore, demonstrated that systemic lupus developed in 7 percent of 148 individuals with chronic false-positive tests for syphilis and that a further 30 percent had symptoms consistent with collagen disease. Friou applied the technique of indirect immunofluorescence to demonstrate the presence of antinuclear antibodies in the blood of individuals with systemic lupus. Subsequently, there was the recognition of antibodies to deoxyribonucleic acid (DNA) and the description of antibodies to extractable nuclear antigens (nuclear ribonucleoprotein [nRNP], Sm, Ro, La), and anticardiolipin antibodies; these autoantibodies are useful in describing clinical subsets and understanding the etiopathogenesis of lupus. The Lupus Erythematosus cell is discovered. This discovery ushered in the present era of the application of immunology to the study of lupus erythematosus; it also allowed the diagnosis of individuals with much milder forms of the disease. This possibility, coupled with the discovery of cortisone as a treatment, changed the natural history of lupus as it was known prior to that time. Two other immunologic markers were recognized in the 1950s as being associated with lupus: the biologic false-positive test for syphilis and the immunofluorescent test for antinuclear antibodies. Moore, working in Baltimore, demonstrated that systemic lupus developed in 7 percent of 148 individuals with chronic false-positive tests for syphilis and that a further 30 percent had symptoms consistent with collagen disease. Friou applied the technique of indirect immunofluorescence to demonstrate the presence of antinuclear antibodies in the blood of individuals with systemic lupus. Subsequently, there was the recognition of antibodies to deoxyribonucleic acid (DNA) and the description of antibodies to extractable nuclear antigens (nuclear ribonucleoprotein [nRNP], Sm, Ro, La), and anticardiolipin antibodies; these autoantibodies are useful in describing clinical subsets and understanding the etiopathogenesis of lupus. Genetic component recognized The familial occurrence of systemic lupus was first noted by Leonhardt in 1954 and later studies by Arnett and Shulman at Johns Hopkins. Subsequently, familial aggregation of lupus, the concordance of lupus in monozygotic twin pairs, and the association of genetic markers with lupus have been described over the past twenty years. Molecular biology techniques have been applied to the study of human lymphocyte antigen (HLA) Class II genes to determine specific amino acid sequences in these cell surface molecules that are involved in antigen presentation to T-helper cells in individuals with lupus. These studies have resulted in the identification of genetic-serologic subsets of systemic lupus that complement the clinico-serologic subsets noted earlier. It is hoped by investigators working in this field that these studies will lead to the identification of etiologic factors (e.g., viral antigens/proteins) in lupus. Over the last decade or so, we have witnessed significant advances in the understanding of the genetic basis of lupus, and of the immunological derangements which lead to the clinical manifestations of the disease. Advances have been made in the assessment of the impact of the disease in general, and in minority population groups, in particular and efforts are being made towards defining lupus biomarkers which may help both to predict disease outcome and to guide treatments. Prevalence and incidence Lupus appears to be a relatively uncommon disease. The prevalence has been estimated in several different countries mostly, however, in the developed world, using different techniques of case ascertainment. The authors of one metaanalysis (including those studies in Europe and North America) suggested an overall weighted mean prevalence of 24/100,000 population.Three English studies have produced prevalence estimates of: 12/100,000, 25/100,000 and 28/100,000 and the only study in N Ireland estimated a rate of 254/100,000. Studies in countries which include predominantly white populations have resulted in lower prevalence estimates (e.g. England) when compared with studies among populations with a significant proportion of Afro-Caribbeans, Asians and Hispanics. It is more difficult to estimate incidence for a rare disease but studies in both North America and Europe have produced estimates that are similar (approximately 1 – 8 cases per 100,000 persons per year).The lowest rates of incidence were seen among Caucasian Americans, Canadians and Spaniards and the highest rates among Asian (10.0 cases /100,000) and Afro-Caribbean (21.9 cases /100,000) residents of the UK. In an average UK practice list of 3000 patients, therefore, a GP would not expect to see a new case of lupus more often than every 7-10 years. Types There are three main types of lupus: Systemic lupus erythematosus (eh-RITH-eh-muh-TOE-sus) is the most common form. It’s sometimes called SLE, or just lupus. The word “systemic” means that the disease can involve many parts of the body such as the heart, lungs, kidneys, and brain. SLE symptoms can be mild or serious. Systemic lupus Discoid lupus erythematosus mainly affects the skin. A red rash may appear, or the skin on the face, scalp, or elsewhere may change color. Discoid lupus Drug-induced lupus is triggered by a few medicines. It’s like SLE, but symptoms are usually milder. Most of the time, the disease goes away when the medicine is stopped. More men develop drug-induced lupus because the drugs that cause it, hydralazine and procainamide, are used to treat heart conditions that are more common in men. Risk factors Risk factors for developing lupus include: Gender – more than 90% of people with lupus are women. Before puberty, boys and girls are equally likely to develop the condition Age – symptoms and diagnosis of lupus often occur between the ages of 15-45. Around 15% of people who are later diagnosed with lupus, experienced symptoms before the age of 18 Race – in the US, lupus is more common, more severe and develops earlier in African-Americans, Hispanics/Latinos, Asian-Americans, Native Americans, Native Hawaiians and Pacific Islanders than in the white population Family history – first-degree or second-degree relatives of a person with lupus have a 4-8% risk of developing lupus. One study suggests that sisters of lupus patients have as high as a 10% chance of developing lupus. In another 10-year prospective study, researchers observed a 7% incidence of lupus in first-degree relatives of lupus patients. Causes Many (but not all) scientists believe that lupus develops in response to a combination of factors both inside and outside the body, including hormones, genetics, and environment. Hormones Hormones are the body’s messengers. They regulate many of the body’s functions. Because nine of every 10 occurrences of lupus are in females, researchers have looked at the relationship between estrogen and lupus. While men and women both produce estrogen, its production is much greater in females. Many women have more lupus symptoms before menstrual periods and/or during pregnancy when estrogen production is high. This may indicate that estrogen somehow regulates the severity of lupus. However, no causal effect has been proven between estrogen, or any other hormone, and lupus. And, studies of women with lupus taking estrogen in either birth control pills or as postmenopausal therapy have shown no increase in significant disease activity. Researchers are now focusing on differences between men and women, beyond hormone levels, which may account for why women are more prone to lupus and other autoimmune diseases. Genetics Researchers have now identified more than 50 genes which they associate with lupus. These genes are more commonly seen in people with lupus than in those without the disease, and while most of these genes have not been shown to directly cause lupus, they are believed to contribute to it. In most cases, genes are not enough. This is especially evident with twins who are raised in the same environment and have the same inherited features yet only one develops lupus. Although, when one of two identical twins has lupus, there is an increased chance that the other twin will also develop the disease (30% percent chance for identical twins; 5-10% percent chance for fraternal twins). Lupus can develop in people with no family history of it, but there are likely to be other autoimmune diseases in some family members. Certain ethnic groups (people of African, Asian, Hispanic/Latino, Native American, Native Hawaiian, or Pacific Island descent) have a greater risk of developing lupus, which may be related to genes they have in common. Environment Most researchers today think that an environmental agent, such as a virus or possibly a chemical, randomly encountered by a genetically susceptible individual, acts to trigger the disease. Researchers have not identified a specific environmental agent as yet but the hypothesis remains likely. While the environmental elements that can trigger lupus and cause flares aren’t fully known, the most commonly cited are ultraviolet light (UVA and UVB); infections (including the effects of the Epstein-Barr virus), and exposure to silica dust in agricultural or industrial settings. Symptoms Lupus can have many symptoms, and they differ from person to person. Some of the more common ones are Pain or swelling in joints Muscle pain Fever with no known cause Red rashes, most often on the face (also called the “butterfly rash”) Chest pain when taking a deep breath Hair loss Pale or purple fingers or toes Sensitivity to the sun Swelling in legs or around eyes Mouth ulcers Swollen glands Feeling very tired Symptoms may come and go. When you are having symptoms, it is called a flare. Flares can range from mild to severe. New symptoms may appear at any time. Diagnosis and test Diagnosing lupus is difficult because signs and symptoms vary considerably from person to person. Signs and symptoms of lupus may vary over time and overlap with those of many other disorders. No one test can diagnose lupus. The combination of blood and urine tests, signs and symptoms, and physical examination findings leads to the diagnosis. Laboratory tests Blood and urine tests may include: Complete blood count: This test measures the number of red blood cells, white blood cells and platelets as well as the amount of hemoglobin, a protein in red blood cells. Results may indicate you have anemia, which commonly occurs in lupus. A low white blood cell or platelet count may occur in lupus as well. Erythrocyte sedimentation rate: This blood test determines the rate at which red blood cells settle to the bottom of a tube in an hour. A faster than normal rate may indicate a systemic disease, such as lupus. The sedimentation rate isn’t specific for any one disease. It may be elevated if you have lupus, another inflammatory condition, cancer or an infection. Kidney and liver assessment: Blood tests can assess how well your kidneys and liver are functioning. Lupus can affect these organs. Urinalysis. An examination of a sample of your urine may show an increased protein level or red blood cells in the urine, which may occur if lupus has affected your kidneys. Antinuclear antibody (ANA) test. A positive test for the presence of these antibodies — produced by your immune system — indicates a stimulated immune system. While most people with lupus have a positive ANA test, most people with a positive ANA do not have lupus. If you test positive for ANA, your doctor may advise more-specific antibody testing. Imaging tests If your doctor suspects that lupus is affecting your lungs or heart, he or she may suggest: Chest X-ray. An image of your chest may reveal abnormal shadows that suggest fluid or inflammation in your lungs. Echocardiogram. This test uses sound waves to produce real-time images of your beating heart. It can check for problems with your valves and other portions of your heart. Biopsy Lupus can harm your kidneys in many different ways, and treatments can vary, depending on the type of damage that occurs. In some cases, it’s necessary to test a small sample of kidney tissue to determine what the best treatment might be. The sample can be obtained with a needle or through a small incision. Treatment and medications Treatment for lupus depends on your signs and symptoms. Determining whether your signs and symptoms should be treated and what medications to use requires a careful discussion of the benefits and risks with your doctor. As your signs and symptoms flare and subside, you and your doctor may find that you’ll need to change medications or dosages. The medications most commonly used to control lupus include: Nonsteroidal anti-inflammatory drugs (NSAIDs): Over-the-counter NSAIDs, such as naproxen sodium (Aleve) and ibuprofen (Advil, Motrin IB, others), may be used to treat pain, swelling and fever associated with lupus. Stronger NSAIDs are available by prescription. Side effects of NSAIDs include stomach bleeding, kidney problems and an increased risk of heart problems. Antimalarial drugs: Medications commonly used to treat malaria, such as hydroxychloroquine (Plaquenil), also can help control lupus. Side effects can include stomach upset and, very rarely, damage to the retina of the eye. Corticosteroids: Prednisone and other types of corticosteroids can counter the inflammation of lupus but often produce long-term side effects including weight gain, easy bruising, thinning bones (osteoporosis), high blood pressure, diabetes and increased risk of infection. The risk of side effects increases with higher doses and longer term therapy. Immunosuppressants: Drugs that suppress the immune system may be helpful in serious cases of lupus. Examples include azathioprine (Imuran, Azasan), mycophenolate (CellCept), leflunomide (Arava) and methotrexate (Trexall). Potential side effects may include an increased risk of infection, liver damage, decreased fertility and an increased risk of cancer. A newer medication, belimumab (Benlysta), also reduces lupus symptoms in some people. Side effects include nausea, diarrhea and fever. Prevention There is no known way to prevent Lupus since there is no known cause as yet. You can help manage flare-ups though: Avoid known triggers such as sunlight, stress, and lack of sleep Manage your diet Get adequate exerciseDr. Nitin Kanholkar1 Like7 Answers